Últimas publicaciones
Aspetti psicologici del tumore del polmone. Capitolo del libro “Psiconcologia"
P. Catanzaro, V. Gregorc.
Mesotelioma, Eziopatogenesi, presentazione clinica e percorso diagnostico-terapeutico
Medicina e Diritto 3/2009, Sessione Focus. pg 14-23, Maggioli Editore
Ghio D, Gregorc V.
Relevance Of P53, Bcl-2 And Rb Expression On Resistance To Cisplatin-Based Chemotherapy In Advanced Non Small Cell Lung Cancer (NSCLC)
Lung Cancer (2003) 41-48
V. Gregorc, V. Ludovini, L. Pistola, S. Darwish, I. Floriani, G. Bellezza, A. Sidoni, A. Cavaliere, M. Scheibel, V. De Angelis, E. Bucciarelli, M. Tonato.
Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer
Cancer. 2007 Aug 15;110(4):845-53.
Gregorc V, Spreafico A, Floriani I, Colombo B, Ludovini V, Pistola L, Bellezza G, Vigano MG, Villa E, Corti A.
Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib
Clin Pharmacol Ther. 2008 Mar;83(3):477-84.
Gregorc V, Hidalgo M, Spreafico A, Cusatis G, Ludovini V, Ingersoll RG, Marsh S, Steinberg SM, Viganò MG, Ghio D, Villa E, Sparreboom A, Baker SD.
Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours
Br J Cancer. 2009 Jul 21;101(2):21924.
Gregorc V, Santoro A, Bennicelli E, Punt CJ, Citterio G, Timmer-Bonte JN, Caligaris Cappio F, Lambiase A, Bordignon C, van Herpen CM.
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.
Lancet Oncol. 2014 Jun;15(7):713-21.
Gregorc V, Novello S, Lazzari C, Barni S, Aieta M, Mencoboni M, Grossi F, Pas TD, de Marinis F, Bearz A, Floriani I, Torri V, Bulotta A, Cattaneo A, Grigorieva J, Tsypin M, Roder J, Doglioni C, Levra MG, Petrelli F, Foti S, Viganò M, Bachi A, Roder H.
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line PlatinumBased Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor
The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial J Thorac Oncol. J Thorac Oncol. 2017 Apr;12(4):752-762
Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AM, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJ,
Combined exosomal RNA and circulating tumor DNA for epidermal growth factor mutation detection in non-small cell lung cancer
J Thorac Dis. 2018 Nov;10(Suppl 33):S4023-S4027. doi: 10.21037/jtd.2018.10.17.
Petrelli F, Lazzari C, Ardito R, Borgonovo K, Bulotta A, Conti B, Cabiddu M, Capitanio JF, Brighenti M, Ghilardi M, Gianni L, Barni S, Gregorc V. Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies. PLoS One. 2018 Jul 27;13(7):e0201425. doi: 10.1371/journal.pone.0201425. eCollection 2018. Lazzari C, Gregorc V, Cangi MG, Giovannetti E, Bulotta
PD-1 Inhibitors-Related Neurological Toxicities in Patients with Non-Small-Cell Lung Cancer: A Literature Review. Cancers (Basel)
2019 Mar 1;11(3). pii: E296. doi: 10.3390/cancers11030296.
Mirabile A, Brioschi E, Ducceschi M, Piva S, Lazzari C, Bulotta A, Viganò MG, Petrella G, Gianni L, Gregorc V.
